logo

Inovio Pharmaceuticals Inc. (INO)



Trade INO now with
  Date
  Headline
5/21/2018 8:02:21 AM Inovio Opens Phase 2 Trial For VGX-3100 In Third Indication To Treat HPV
5/17/2018 8:02:44 AM Inovio Pharma Demonstrates PSA Stabilizing Effect Of INO-5150 Immunotherapy In Phase 1b Study For Prostate Cancer
5/9/2018 4:07:31 PM Inovio Pharmaceuticals Q1 Loss/share $0.36 Vs. Loss $0.31 Year Ago
4/11/2018 8:03:22 AM Inovio To Receive Up To $56 Mln From CEPI To Advance DNA Vaccines Against Lassa Fever And MERS
3/20/2018 8:02:09 AM Inovio Closes License And Collaboration Agreement With ApolloBio To Commercialize VGX-3100 In Greater China
3/14/2018 4:09:00 PM Inovio Pharmaceuticals Q4 Loss/shar $0.24 Vs. Loss $0.35 Year Ago
1/9/2018 8:05:19 AM Inovio And Parker Institute For Cancer Immunotherapy Collaborate To Evaluate Novel Cancer Immunotherapy Combinations
1/8/2018 8:07:59 AM Inovio Receives Milestone Payment From MedImmune
1/2/2018 8:03:13 AM Inovio Enters License, Collaboration Agreement With ApolloBio To Develop VGX-3100 In China
12/6/2017 8:02:03 AM Inovio Pharmaceuticals Adds Wendy Yarno To Board
11/29/2017 8:04:33 AM Inovio’s Analysis Of VGX-3100 Phase 2b Data Reveals Immune Correlates And Biomarker Signatures That Predicted Efficacy